{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:05:27Z","timestamp":1784203527703,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06071-9","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:19:39Z","timestamp":1784200779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Potential of Mesenchymal Stem Cells in Multiple Sclerosis: An Updated Review"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5967-9125","authenticated-orcid":false,"given":"Irem","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigir","family":"Biray Avci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"6071_CR1","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.3836","author":"J Kami\u0144ska","year":"2017","unstructured":"Kami\u0144ska J, Koper OM, Piechal K, Kemona H (2017) Multiple sclerosis - etiology and diagnostic potential. Postepy Hig Med Dosw(Online). https:\/\/doi.org\/10.5604\/01.3001.0010.3836","journal-title":"Postepy Hig Med Dosw(Online)"},{"issue":"6","key":"6071_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/eji.202149757","volume":"52","author":"B Engelhardt","year":"2022","unstructured":"Engelhardt B, Comabella M, Chan A (2022) Multiple sclerosis: immunopathological heterogeneity and its implications. Eur J Immunol 52(6):869\u2013881. https:\/\/doi.org\/10.1002\/eji.202149757","journal-title":"Eur J Immunol"},{"key":"6071_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.81","author":"PA Muraro","year":"2017","unstructured":"Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. https:\/\/doi.org\/10.1038\/nrneurol.2017.81","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"6071_CR4","doi-asserted-by":"publisher","first-page":"E37297","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA (2024) Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Med (United States) 103(8):E37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297","journal-title":"Med (United States)"},{"key":"6071_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049","journal-title":"Am J Med"},{"key":"6071_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/nri3871","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"key":"6071_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis \u2013 a review. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.13819","journal-title":"Eur J Neurol"},{"issue":"3","key":"6071_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/13524585221130941","volume":"29","author":"WJ Brownlee","year":"2023","unstructured":"Brownlee WJ et al (2023) HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis. Mult Scler J 29(3):333\u2013342. https:\/\/doi.org\/10.1177\/13524585221130941","journal-title":"Mult Scler J"},{"issue":"4","key":"6071_CR9","doi-asserted-by":"publisher","first-page":"e13041","DOI":"10.1111\/BPA.13041;CTYPE:STRING:JOURNAL","volume":"32","author":"RL Yates","year":"2022","unstructured":"Yates RL et al (2022) The influence of HLA-DRB1*15 on the relationship between microglia and neurons in multiple sclerosis normal appearing cortical grey matter. Brain Pathol 32(4):e13041. https:\/\/doi.org\/10.1111\/BPA.13041;CTYPE:STRING:JOURNAL","journal-title":"Brain Pathol"},{"key":"6071_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028944","author":"L Alfredsson","year":"2019","unstructured":"Alfredsson L, Olsson T (2019) Lifestyle and environmental factors in multiple sclerosis. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a028944","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6071_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514554054","author":"V Sinay","year":"2015","unstructured":"Sinay V, Perez Akly M, Zanga G, Ciardi C, Racosta JM (2015) School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/1352458514554054","journal-title":"Mult Scler"},{"issue":"10","key":"6071_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2024","unstructured":"Montalban X et al (2024) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24(10):850\u2013865. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"6071_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.907","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. https:\/\/doi.org\/10.1212\/WNL.46.4.907","journal-title":"Neurology"},{"key":"6071_CR14","doi-asserted-by":"publisher","unstructured":"Lublin FD et al (2014) Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000000560.","DOI":"10.1212\/WNL.0000000000000560"},{"key":"6071_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Multiple sclerosis pathology. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a028936","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6071_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2017.08.002","author":"HN Lemus","year":"2018","unstructured":"Lemus HN, Warrington AE, Rodriguez M (2018) Multiple sclerosis: Mechanisms of disease and strategies for myelin and axonal repair. Neurol Clin. https:\/\/doi.org\/10.1016\/j.ncl.2017.08.002","journal-title":"Neurol Clin"},{"key":"6071_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6071_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra052130","author":"EM Frohman","year":"2006","unstructured":"Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis \u2014 The plaque and its pathogenesis. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmra052130","journal-title":"N Engl J Med"},{"key":"6071_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Br\u00fcck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. https:\/\/doi.org\/10.1002\/1531-8249(200006)47:6%3c707::AID-ANA3%3e3.0.CO;2-Q","journal-title":"Ann Neurol"},{"key":"6071_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(00)00409-4","author":"AH Cross","year":"2001","unstructured":"Cross AH, Trotter JL, Lyons JA (2001) B cells and antibodies in CNS demyelinating disease. J Neuroimmunol. https:\/\/doi.org\/10.1016\/S0165-5728(00)00409-4","journal-title":"J Neuroimmunol"},{"issue":"1","key":"6071_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"6071_CR22","doi-asserted-by":"publisher","first-page":"e12712","DOI":"10.1111\/CPR.12712","volume":"53","author":"W Jiang","year":"2019","unstructured":"Jiang W, Xu J (2019) Immune modulation by mesenchymal stem cells. Cell Prolif 53(1):e12712. https:\/\/doi.org\/10.1111\/CPR.12712","journal-title":"Cell Prolif"},{"issue":"18","key":"6071_CR23","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.3390\/IJMS221810045","volume":"22","author":"PT Do","year":"2021","unstructured":"Do PT, Wu CC, Chiang YH, Hu CJ, Chen KY (2021) Mesenchymal stem\/stromal cell therapy in blood\u2013brain barrier preservation following ischemia: molecular mechanisms and prospects. Int J Mol Sci 22(18):10045. https:\/\/doi.org\/10.3390\/IJMS221810045","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6071_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/IJMS25031365","volume":"25","author":"S Gavasso","year":"2024","unstructured":"Gavasso S et al (2024) The therapeutic mechanisms of mesenchymal stem cells in MS\u2014a review focusing on neuroprotective properties. Int J Mol Sci 25(3):1365. https:\/\/doi.org\/10.3390\/IJMS25031365","journal-title":"Int J Mol Sci"},{"key":"6071_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16059283","author":"J Xiao","year":"2015","unstructured":"Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W (2015) Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms16059283","journal-title":"Int J Mol Sci"},{"key":"6071_CR26","doi-asserted-by":"publisher","DOI":"10.1242\/dev.110.4.1001","author":"CS Potten","year":"1990","unstructured":"Potten CS, Loeffler M (1990) Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development. https:\/\/doi.org\/10.1242\/dev.110.4.1001","journal-title":"Development"},{"key":"6071_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diff.2016.02.005","author":"SG Almalki","year":"2016","unstructured":"Almalki SG, Agrawal DK (2016) Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation. https:\/\/doi.org\/10.1016\/j.diff.2016.02.005","journal-title":"Differentiation"},{"issue":"4","key":"6071_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315\u2013317. https:\/\/doi.org\/10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"6071_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.1970.tb00347.x","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Prolif. https:\/\/doi.org\/10.1111\/j.1365-2184.1970.tb00347.x","journal-title":"Cell Prolif"},{"key":"6071_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.01.007","author":"Y Chen","year":"2008","unstructured":"Chen Y, Shao JZ, Xiang LX, Dong XJ, Zhang GR (2008) Mesenchymal stem cells: A promising candidate in regenerative medicine. Int J Biochem Cell Biol. https:\/\/doi.org\/10.1016\/j.biocel.2008.01.007","journal-title":"Int J Biochem Cell Biol"},{"key":"6071_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66916-4","author":"MJD Griffiths","year":"2005","unstructured":"Griffiths MJD, Bonnet D, Janes SM (2005) Stem cells of the alveolar epithelium. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(05)66916-4","journal-title":"Lancet"},{"key":"6071_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P","author":"C De Bari","year":"2001","unstructured":"De Bari C, Dell\u2019Accio F, Tylzanowski P, Luyten FP (2001) Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. https:\/\/doi.org\/10.1002\/1529-0131(200108)44:8%3c1928::AID-ART331%3e3.0.CO;2-P","journal-title":"Arthritis Rheum"},{"key":"6071_CR33","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.H.00049","author":"LJ Nesti","year":"2008","unstructured":"Nesti LJ et al (2008) Differentiation potential of multipotent progenitor cells derived from war-traumatized muscle tissue. J Bone Jt Surg. https:\/\/doi.org\/10.2106\/JBJS.H.00049","journal-title":"J Bone Jt Surg"},{"key":"6071_CR34","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.4.696","author":"S Shi","year":"2003","unstructured":"Shi S, Gronthos S (2003) Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res. https:\/\/doi.org\/10.1359\/jbmr.2003.18.4.696","journal-title":"J Bone Miner Res"},{"key":"6071_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/14653240310004539","author":"L Aust","year":"2004","unstructured":"Aust L et al (2004) Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. https:\/\/doi.org\/10.1080\/14653240310004539","journal-title":"Cytotherapy"},{"key":"6071_CR36","doi-asserted-by":"publisher","unstructured":"in \u2019t Anker PS et al (2004) Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. https:\/\/doi.org\/10.1634\/stemcells.2004-0058","DOI":"10.1634\/stemcells.2004-0058"},{"key":"6071_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2006.03.009","author":"Z Miao","year":"2006","unstructured":"Miao Z et al (2006) Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int. https:\/\/doi.org\/10.1016\/j.cellbi.2006.03.009","journal-title":"Cell Biol Int"},{"key":"6071_CR38","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0013","author":"H Wang","year":"2004","unstructured":"Wang H et al (2004) Mesenchymal stem cells in the Wharton\u2019s jelly of the human umbilical cord. Stem Cells. https:\/\/doi.org\/10.1634\/stemcells.2004-0013","journal-title":"Stem Cells"},{"key":"6071_CR39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01986.x","author":"A Erices","year":"2000","unstructured":"Erices A, Conget P, Minguell JJ (2000) Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01986.x","journal-title":"Br J Haematol"},{"key":"6071_CR40","doi-asserted-by":"publisher","DOI":"10.12717\/dr.2017.21.1.001","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Park J-S (2017) Usage of human mesenchymal stem cells in cell-based therapy: advantages and disadvantages. Dev Reprod. https:\/\/doi.org\/10.12717\/dr.2017.21.1.001","journal-title":"Dev Reprod"},{"key":"6071_CR41","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0031","author":"B Lo","year":"2009","unstructured":"Lo B, Parham L (2009) Ethical issues in stem cell research. Endocr Rev. https:\/\/doi.org\/10.1210\/er.2008-0031","journal-title":"Endocr Rev"},{"key":"6071_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5391.1145","author":"JA Thomson","year":"1998","unstructured":"Thomson JA (1998) Embryonic stem cell lines derived from human blastocysts. Science (1979). https:\/\/doi.org\/10.1126\/science.282.5391.1145","journal-title":"Science (1979)"},{"key":"6071_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.024","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. https:\/\/doi.org\/10.1016\/j.cell.2006.07.024","journal-title":"Cell"},{"key":"6071_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002944","author":"A Andrzejewska","year":"2021","unstructured":"Andrzejewska A, Dabrowska S, Lukomska B, Janowski M (2021) Mesenchymal stem cells for neurological disorders. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202002944","journal-title":"Adv Sci"},{"key":"6071_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.05.010","author":"RJM Franklin","year":"2015","unstructured":"Franklin RJM (2015) Regenerative medicines for remyelination: from aspiration to reality. Cell Stem Cell. https:\/\/doi.org\/10.1016\/j.stem.2015.05.010","journal-title":"Cell Stem Cell"},{"key":"6071_CR46","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.175050","author":"LS Tejedor","year":"2016","unstructured":"Tejedor LS, Skripuletz T, Stangel M, Gudi V (2016) Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis. Neural Regen Res. https:\/\/doi.org\/10.4103\/1673-5374.175050","journal-title":"Neural Regen Res"},{"key":"6071_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reth.2022.07.003","volume":"21","author":"A Alanazi","year":"2022","unstructured":"Alanazi A, Alassiri M, Jawdat D, Almalik Y (2022) Mesenchymal stem cell therapy: a review of clinical trials for multiple sclerosis. Regen Ther 21:201\u2013209. https:\/\/doi.org\/10.1016\/j.reth.2022.07.003","journal-title":"Regen Ther"},{"issue":"7","key":"6071_CR48","doi-asserted-by":"publisher","first-page":"9298","DOI":"10.3390\/IJMS13079298","volume":"13","author":"MA Al Jumah","year":"2012","unstructured":"Al Jumah MA, Abumaree MH (2012) The Immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): A model of multiple sclerosis (MS). Int J Mol Sci 13(7):9298\u20139331. https:\/\/doi.org\/10.3390\/IJMS13079298","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6071_CR49","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/NEN.0B013E3181F97392","volume":"69","author":"D Gordon","year":"2010","unstructured":"Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ (2010) Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 69(11):1087\u20131095. https:\/\/doi.org\/10.1097\/NEN.0B013E3181F97392","journal-title":"J Neuropathol Exp Neurol"},{"key":"6071_CR50","doi-asserted-by":"publisher","first-page":"1024058","DOI":"10.3389\/FNMOL.2022.1024058\/FULL","volume":"15","author":"RR Voskuhl","year":"2022","unstructured":"Voskuhl RR, MacKenzie-Graham A (2022) Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis. Front Mol Neurosci 15:1024058. https:\/\/doi.org\/10.3389\/FNMOL.2022.1024058\/FULL","journal-title":"Front Mol Neurosci"},{"issue":"1\u20132","key":"6071_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/J.JNS.2007.05.005","volume":"265","author":"D Karussis","year":"2008","unstructured":"Karussis D, Kassis I, Kurkalli BGS, Slavin S (2008) Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological\/neurodegenerative diseases. J Neurol Sci 265(1\u20132):131\u2013135. https:\/\/doi.org\/10.1016\/J.JNS.2007.05.005","journal-title":"J Neurol Sci"},{"key":"6071_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apm.13456","volume":"4","author":"A Sadeghnejad","year":"2024","unstructured":"Sadeghnejad A et al (2024) Exploring the role of mesenchymal stem cells in modulating immune responses via Treg and Th2 cell activation: insights from mouse model of multiple sclerosis. APMIS 4:1\u201312. https:\/\/doi.org\/10.1111\/apm.13456","journal-title":"APMIS"},{"key":"6071_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.05.005","author":"Y Xin","year":"2020","unstructured":"Xin Y et al (2020) Changes of immune parameters of T lymphocytes and macrophages in EAE mice after BM-MSCs transplantation. Immunol Lett. https:\/\/doi.org\/10.1016\/j.imlet.2020.05.005","journal-title":"Immunol Lett"},{"issue":"5","key":"6071_CR54","doi-asserted-by":"publisher","first-page":"e0243014","DOI":"10.1371\/JOURNAL.PONE.0243014","volume":"16","author":"GY Liu","year":"2021","unstructured":"Liu GY, Wu Y, Kong FY, Ma S, Fu LY, Geng J (2021) BMSCs differentiated into neurons, astrocytes and oligodendrocytes alleviated the inflammation and demyelination of EAE mice models. PLoS ONE 16(5):e0243014. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0243014","journal-title":"PLoS ONE"},{"key":"6071_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20841","author":"L Bai","year":"2009","unstructured":"Bai L et al (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. https:\/\/doi.org\/10.1002\/glia.20841","journal-title":"Glia"},{"key":"6071_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.6.753","author":"I Kassis","year":"2008","unstructured":"Kassis I et al (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. https:\/\/doi.org\/10.1001\/archneur.65.6.753","journal-title":"Arch Neurol"},{"key":"6071_CR57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1496","author":"E Zappia","year":"2005","unstructured":"Zappia E et al (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. https:\/\/doi.org\/10.1182\/blood-2005-04-1496","journal-title":"Blood"},{"key":"6071_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.03.018","author":"J Zhang","year":"2005","unstructured":"Zhang J et al (2005) Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2005.03.018","journal-title":"Exp Neurol"},{"issue":"3","key":"6071_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/JNR.20962","volume":"84","author":"J Zhang","year":"2006","unstructured":"Zhang J et al (2006) Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res 84(3):587\u2013595. https:\/\/doi.org\/10.1002\/JNR.20962","journal-title":"J Neurosci Res"},{"issue":"1","key":"6071_CR60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/S12031-009-9302-8\/FIGURES\/5","volume":"41","author":"Y Barhum","year":"2010","unstructured":"Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D (2010) Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 41(1):129\u2013137. https:\/\/doi.org\/10.1007\/S12031-009-9302-8\/FIGURES\/5","journal-title":"J Mol Neurosci"},{"key":"6071_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113895","author":"J Zhang","year":"2022","unstructured":"Zhang J et al (2022) Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113895","journal-title":"Exp Neurol"},{"issue":"1","key":"6071_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13287-025-04401-7\/FIGURES\/7","volume":"16","author":"X Xiu","year":"2025","unstructured":"Xiu X et al (2025) Synergistic potential of bone marrow mesenchymal stem cells and miR181-a combinational therapy against multiple sclerosis. Stem Cell Res Ther 16(1):1\u201315. https:\/\/doi.org\/10.1186\/S13287-025-04401-7\/FIGURES\/7","journal-title":"Stem Cell Res Ther"},{"key":"6071_CR63","doi-asserted-by":"publisher","first-page":"114593","DOI":"10.1016\/J.BIOPHA.2023.114593","volume":"162","author":"J Fan","year":"2023","unstructured":"Fan J et al (2023) Mesenchymal stem cell-derived exosomal microRNA-367\u20133p alleviates experimental autoimmune encephalomyelitis via inhibition of microglial ferroptosis by targeting EZH2. Biomed Pharmacother 162:114593. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114593","journal-title":"Biomed Pharmacother"},{"key":"6071_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.07.016","author":"F Yousefi","year":"2013","unstructured":"Yousefi F, Ebtekar M, Soleimani M, Soudi S, Hashemi SM (2013) Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2013.07.016","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"6071_CR65","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/CBIN.12171","volume":"48","author":"S Zargarani","year":"2024","unstructured":"Zargarani S et al (2024) Adipose-derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1\/Th17 and expansion of Th2\/Treg responses. Cell Biol Int 48(8):1124\u20131137. https:\/\/doi.org\/10.1002\/CBIN.12171","journal-title":"Cell Biol Int"},{"key":"6071_CR66","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2012.0463","author":"R Liu","year":"2013","unstructured":"Liu R et al (2013) Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev. https:\/\/doi.org\/10.1089\/scd.2012.0463","journal-title":"Stem Cells Dev"},{"issue":"1","key":"6071_CR67","doi-asserted-by":"publisher","first-page":"105487","DOI":"10.1016\/J.JBC.2023.105487","volume":"300","author":"D Qin","year":"2024","unstructured":"Qin D, Wang C, Li D, Guo S (2024) Exosomal miR-23a-3p derived from human umbilical cord mesenchymal stem cells promotes remyelination in central nervous system demyelinating diseases by targeting Tbr1\/Wnt pathway. J Biol Chem 300(1):105487. https:\/\/doi.org\/10.1016\/J.JBC.2023.105487","journal-title":"J Biol Chem"},{"key":"6071_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02563-8","author":"C Brown","year":"2021","unstructured":"Brown C, McKee C, Halassy S, Kojan S, Feinstein DL, Chaudhry GR (2021) Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Stem Cell Res Ther. https:\/\/doi.org\/10.1186\/s13287-021-02563-8","journal-title":"Stem Cell Res Ther"},{"key":"6071_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306573.25","author":"P Connick","year":"2013","unstructured":"Connick P, Chandran S (2013) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open\u2013label phase 2A proof\u2013of\u2013concept study. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2013-306573.25","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6071_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.248","author":"D Karussis","year":"2010","unstructured":"Karussis D et al (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. https:\/\/doi.org\/10.1001\/archneurol.2010.248","journal-title":"Arch Neurol"},{"key":"6071_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.891514","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, Kr\u00e5kenes T, Gjerde C, Mustafa K, Rekand T, B\u00f8 L (2022) Safety and clinical efficacy of mesenchymal stem cell treatment in traumatic spinal cord injury, multiple sclerosis and ischemic stroke \u2013 a systematic review and meta-analysis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.891514","journal-title":"Front Neurol"},{"key":"6071_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113936","author":"S Llufriu","year":"2014","unstructured":"Llufriu S et al (2014) Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0113936","journal-title":"PLoS ONE"},{"key":"6071_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.44","author":"CM Rice","year":"2010","unstructured":"Rice CM et al (2010) Safey and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther. https:\/\/doi.org\/10.1038\/clpt.2010.44","journal-title":"Clin Pharmacol Ther"},{"key":"6071_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.07.013","author":"B Yamout","year":"2010","unstructured":"Yamout B et al (2010) Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.07.013","journal-title":"J Neuroimmunol"},{"key":"6071_CR75","doi-asserted-by":"publisher","first-page":"639315","DOI":"10.3389\/FNEUR.2021.639315\/BIBTEX","volume":"12","author":"P Petrou","year":"2021","unstructured":"Petrou P et al (2021) Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis. Front Neurol 12:639315. https:\/\/doi.org\/10.3389\/FNEUR.2021.639315\/BIBTEX","journal-title":"Front Neurol"},{"issue":"4","key":"6071_CR76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458517703802\/SUPPL_FILE\/MSJ703802_SUPPLEMENTARY_APPENDIX.PDF","volume":"24","author":"JA Cohen","year":"2018","unstructured":"Cohen JA et al (2018) Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler J 24(4):501\u2013511. https:\/\/doi.org\/10.1177\/1352458517703802\/SUPPL_FILE\/MSJ703802_SUPPLEMENTARY_APPENDIX.PDF","journal-title":"Mult Scler J"},{"key":"6071_CR77","doi-asserted-by":"publisher","unstructured":"Islam MA et al (2023) Mesenchymal stem cell therapy in multiple sclerosis: A systematic review and meta-analysis. J Clin Med 12(19). https:\/\/doi.org\/10.3390\/JCM12196311.","DOI":"10.3390\/JCM12196311"},{"key":"6071_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-62","author":"P Connick","year":"2011","unstructured":"Connick P et al (2011) The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. https:\/\/doi.org\/10.1186\/1745-6215-12-62","journal-title":"Trials"},{"issue":"1","key":"6071_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/S13287-025-04184-X","volume":"16","author":"L Zeng","year":"2025","unstructured":"Zeng L et al (2025) Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther 16(1):65. https:\/\/doi.org\/10.1186\/S13287-025-04184-X","journal-title":"Stem Cell Res Ther"},{"key":"6071_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.19-0202","author":"M Kabat","year":"2020","unstructured":"Kabat M, Bobkov I, Kumar S, Grumet M (2020) Trends in mesenchymal stem cell clinical trials 2004\u20132018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. https:\/\/doi.org\/10.1002\/sctm.19-0202","journal-title":"Stem Cells Transl Med"},{"key":"6071_CR81","doi-asserted-by":"publisher","DOI":"10.5772\/INTECHOPEN.76718","author":"P de la Torre","year":"2018","unstructured":"de la Torre P, P\u00e9rez-Lorenzo MJ, Flores AI, de la Torre P, P\u00e9rez-Lorenzo MJ, Flores AI (2018) Human placenta-derived mesenchymal stromal cells: A review from basic research to clinical applications. Stromal Cells - Struct Funct Ther Implic. https:\/\/doi.org\/10.5772\/INTECHOPEN.76718","journal-title":"Stromal Cells - Struct Funct Ther Implic"},{"issue":"1","key":"6071_CR82","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/JCP.22329","volume":"226","author":"TC Tran","year":"2011","unstructured":"Tran TC et al (2011) Identification of human placenta-derived mesenchymal stem cells involved in re-endothelialization. J Cell Physiol 226(1):224\u2013235. https:\/\/doi.org\/10.1002\/JCP.22329","journal-title":"J Cell Physiol"},{"key":"6071_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.08.002","author":"FD Lublin","year":"2014","unstructured":"Lublin FD et al (2014) Human placenta-derived cells(pda-001) for the treatment of adults with multiple sclerosis: a randomized,placebo-controlled, multiple-dose study. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2014.08.002","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"6071_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-025-00590-6","volume":"15","author":"A Shokati","year":"2025","unstructured":"Shokati A et al (2025) Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial. Sci Rep 15(1):1\u201314. https:\/\/doi.org\/10.1038\/S41598-025-00590-6","journal-title":"Sci Rep"},{"key":"6071_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.08.036","author":"VK Harris","year":"2012","unstructured":"Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA (2012) Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. https:\/\/doi.org\/10.1016\/j.jns.2011.08.036","journal-title":"J Neurol Sci"},{"issue":"7","key":"6071_CR86","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5966\/SCTM.2012-0015","volume":"1","author":"VK Harris","year":"2012","unstructured":"Harris VK, Faroqui R, Vyshkina T, Sadiq SA (2012) Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med 1(7):536\u2013547. https:\/\/doi.org\/10.5966\/SCTM.2012-0015","journal-title":"Stem Cells Transl Med"},{"key":"6071_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290069","author":"VK Harris","year":"2023","unstructured":"Harris VK, Wollowitz J, Greenwald J, Carlson AL, Sadiq SA (2023) Mesenchymal stem cell-neural progenitors are enriched in cell signaling molecules implicated in their therapeutic effect in multiple sclerosis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0290069","journal-title":"PLoS ONE"},{"key":"6071_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.02.002","author":"VK Harris","year":"2018","unstructured":"Harris VK et al (2018) Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2018.02.002","journal-title":"EBioMedicine"},{"issue":"1","key":"6071_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/S13287-024-03765-6","volume":"15","author":"VK Harris","year":"2024","unstructured":"Harris VK et al (2024) Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Res Ther 15(1):151. https:\/\/doi.org\/10.1186\/S13287-024-03765-6","journal-title":"Stem Cell Res Ther"},{"key":"6071_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102523","author":"L Mazini","year":"2019","unstructured":"Mazini L, Rochette L, Amine M, Malka G (2019) Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20102523","journal-title":"Int J Mol Sci"},{"key":"6071_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-181","author":"JC Ra","year":"2011","unstructured":"Ra JC et al (2011) Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. https:\/\/doi.org\/10.1186\/1479-5876-9-181","journal-title":"J Transl Med"},{"key":"6071_CR92","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5302120","author":"A Stepien","year":"2016","unstructured":"Stepien A et al (2016) Clinical application of autologous adipose stem cells in patients with multiple sclerosis: preliminary results. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2016\/5302120","journal-title":"Mediators Inflamm"},{"issue":"17","key":"6071_CR93","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/S13287-026-04933-6","volume":"171","author":"FL Arab","year":"2026","unstructured":"Arab FL et al (2026) Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I\/IIa clinical results. Stem Cell Res Ther 171(17):120. https:\/\/doi.org\/10.1186\/S13287-026-04933-6","journal-title":"Stem Cell Res Ther"},{"key":"6071_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10102","author":"Y Akiyama","year":"2002","unstructured":"Akiyama Y, Radtke C, Honmou O, Kocsis JD (2002) Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia. https:\/\/doi.org\/10.1002\/glia.10102","journal-title":"Glia"},{"issue":"12","key":"6071_CR95","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/JCM8122102","volume":"8","author":"E Iacobaeus","year":"2019","unstructured":"Iacobaeus E et al (2019) Short and long term clinical and \u0131mmunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis\u2014A phase I study. J Clin Med 8(12):2102. https:\/\/doi.org\/10.3390\/JCM8122102","journal-title":"J Clin Med"},{"issue":"12","key":"6071_CR96","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1093\/BRAIN\/AWAA333","volume":"143","author":"P Petrou","year":"2020","unstructured":"Petrou P et al (2020) Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 143(12):3574\u20133588. https:\/\/doi.org\/10.1093\/BRAIN\/AWAA333","journal-title":"Brain"},{"issue":"1","key":"6071_CR97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/STCLTM\/SZAB017","volume":"11","author":"P Petrou","year":"2022","unstructured":"Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D (2022) Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Transl Med 11(1):55\u201358. https:\/\/doi.org\/10.1093\/STCLTM\/SZAB017","journal-title":"Stem Cells Transl Med"},{"key":"6071_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104895","author":"SM Nabavi","year":"2023","unstructured":"Nabavi SM et al (2023) Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I\/IIa, double blind, randomized controlled study. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2023.104895","journal-title":"Mult Scler Relat Disord"},{"key":"6071_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.10.032","author":"V Carrai","year":"2013","unstructured":"Carrai V et al (2013) Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. Clin Neurol Neurosurg. https:\/\/doi.org\/10.1016\/j.clineuro.2012.10.032","journal-title":"Clin Neurol Neurosurg"},{"key":"6071_CR100","doi-asserted-by":"publisher","DOI":"10.3727\/096368913X675142","author":"GLV De Oliveira","year":"2015","unstructured":"De Oliveira GLV et al (2015) Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant. https:\/\/doi.org\/10.3727\/096368913X675142","journal-title":"Cell Transplant"},{"key":"6071_CR101","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517711276","author":"J Redondo","year":"2018","unstructured":"Redondo J et al (2018) Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458517711276","journal-title":"Mult Scler J"},{"key":"6071_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.08.007","author":"P Sarkar","year":"2018","unstructured":"Sarkar P et al (2018) Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2017.08.007","journal-title":"Cytotherapy"},{"issue":"6","key":"6071_CR103","doi-asserted-by":"publisher","first-page":"e200444","DOI":"10.1212\/NXI.0000000000200444","volume":"12","author":"R Tanasescu","year":"2025","unstructured":"Tanasescu R et al (2025) Proinflammatory effect of mesenchymal stem cells from patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 12(6):e200444. https:\/\/doi.org\/10.1212\/NXI.0000000000200444","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"6071_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.2843","author":"H Zhang","year":"2012","unstructured":"Zhang H et al (2012) Isolation and characterization of mesenchymal stem cells from whole human umbilical cord applying a single enzyme approach. Cell Biochem Funct. https:\/\/doi.org\/10.1002\/cbf.2843","journal-title":"Cell Biochem Funct"},{"key":"6071_CR105","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0439","author":"DL Troyer","year":"2008","unstructured":"Troyer DL, Weiss ML (2008) Concise review: Wharton\u2019s Jelly-derived cells are a primitive stromal cell population. Stem Cells. https:\/\/doi.org\/10.1634\/stemcells.2007-0439","journal-title":"Stem Cells"},{"key":"6071_CR106","unstructured":"Liu S et al (2019) Therapeutic effect of transplanted umbilical cord mesenchymal stem cells in a cynomolgus monkey model of multiple sclerosis. Am J Transl Res"},{"key":"6071_CR107","unstructured":"Meng M et al (2018) Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis. Am J Transl Res"},{"key":"6071_CR108","doi-asserted-by":"publisher","DOI":"10.3727\/096368914x685005","author":"J-F Li","year":"2014","unstructured":"Li J-F et al (2014) The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. https:\/\/doi.org\/10.3727\/096368914x685005","journal-title":"Cell Transplant"},{"key":"6071_CR109","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509104590","author":"J Liang","year":"2009","unstructured":"Liang J et al (2009) Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/1352458509104590","journal-title":"Mult Scler"},{"key":"6071_CR110","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szac057.014","author":"T Petriv","year":"2022","unstructured":"Petriv T, Tatarchuk M, Tsymbaliyk Y, Rybachuk O, Tsymbaliuk Y, Tsymbaliuk V (2022) Abstract 14 umbilical cord mesenchymal stromal\/stem cells application for spasticity treatment in multiple sclerosis. Stem Cells Transl Med. https:\/\/doi.org\/10.1093\/stcltm\/szac057.014","journal-title":"Stem Cells Transl Med"},{"key":"6071_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02869-4","author":"NH Riordan","year":"2021","unstructured":"Riordan NH et al (2021) Correction to: clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. https:\/\/doi.org\/10.1186\/s12967-021-02869-4","journal-title":"J Transl Med"},{"key":"6071_CR112","doi-asserted-by":"publisher","first-page":"503920","DOI":"10.3389\/FNEUR.2020.00967\/BIBTEX","volume":"11","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ (2020) IV\/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study. Front Neurol 11:503920. https:\/\/doi.org\/10.3389\/FNEUR.2020.00967\/BIBTEX","journal-title":"Front Neurol"},{"key":"6071_CR113","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12345","author":"H Yang","year":"2016","unstructured":"Yang H, Sun J, Wang F, Li Y, Bi J, Qu T (2016) Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.12345","journal-title":"Oncotarget"},{"issue":"2","key":"6071_CR114","doi-asserted-by":"publisher","first-page":"389","DOI":"10.34172\/apb.2022.038","volume":"12","author":"H Baharlooi","year":"2022","unstructured":"Baharlooi H, Salehi Z, Moeini MM, Rezaei N, Azimi M (2022) Immunomodulatory potential of human mesenchymal stem cells and their exosomes on multiple sclerosis. Adv Pharm Bull 12(2):389\u2013397. https:\/\/doi.org\/10.34172\/apb.2022.038","journal-title":"Adv Pharm Bull"},{"key":"6071_CR115","doi-asserted-by":"publisher","DOI":"10.1177\/09636897241233045","author":"F Jamali","year":"2024","unstructured":"Jamali F et al (2024) Human umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis patients: Phase I\/II dose-finding clinical study. Cell Transplant. https:\/\/doi.org\/10.1177\/09636897241233045","journal-title":"Cell Transplant"},{"key":"6071_CR116","doi-asserted-by":"publisher","unstructured":"Valverde-Espinoza JA, Soto-Rodr\u00edguez A, Kop-Montero M, Pastora-Sesin C, Castro S (2024)Protocol for a pilot phase IIa randomized, placebo-controlled, double-blind, crossover study of umbilical cord-derived mesenchymal stem cells (UCMSC) for the treatment of relapsing-remitting multiple sclerosis (RRMS):The MSCell study. Princ Pract Clin Res 10(3).\u00a0https:\/\/doi.org\/10.21801\/PPCRJ.2024.103.4","DOI":"10.21801\/PPCRJ.2024.103.4"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06071-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:19:41Z","timestamp":1784200781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6071"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06071-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"773"}}